- Home
- MREO vs ESLA Comparison
MREO vs ESLA Comparison
Compare MREO & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | ESLA |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 60.9M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | MREO | ESLA |
|---|---|---|
| Price | $0.33 | $1.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 1 |
| Target Price | $1.50 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.4M | 173.3K |
| Earning Date | 05-12-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $6,000.20 | N/A |
| Revenue Next Year | $34.71 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.78 |
| 52 Week High | $2.94 | $3.15 |
Technical Indicators
Market Signals| Indicator | MREO | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 67.21 |
| Support Level | $0.32 | $1.48 |
| Resistance Level | $0.42 | $2.22 |
| Average True Range (ATR) | 0.02 | 0.20 |
| MACD | 0.01 | 0.08 |
| Stochastic Oscillator | 29.29 | 64.28 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.